<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Circulating immune complexes (CIC) were measured by C1q-solid phase method in ninety-five patients with various <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The results showed significantly higher CIC levels in patients with <z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and <z:hpo ids='HP_0001973'>idiopathic thrombocytopenic purpura</z:hpo> (<z:chebi fb="0" ids="16039">ITP</z:chebi>) than CIC levels in <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="2" pm="."><plain>However, there was no significant difference in such levels in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> when compared to <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, the level of CIC did not relate to prognosis for patients with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The findings demonstrated that a high level of CIC in patients with <z:chebi fb="0" ids="16039">ITP</z:chebi> usually responded poorly to steroid treatment </plain></SENT>
<SENT sid="5" pm="."><plain>Other <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi> were indicated in these cases </plain></SENT>
<SENT sid="6" pm="."><plain>Therefore, the CIC level may serve as a therapeutic guide for the treatment of patients with <z:chebi fb="0" ids="16039">ITP</z:chebi> </plain></SENT>
</text></document>